DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pulmonary Arterial Hypertension market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Insights

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term PAH describes a subset of patients who also have the presence of precapillary hypertension, including an end-expiratory pulmonary artery wedge pressure (less than 15 mm Hg) and a pulmonary vascular resistance greater than 3 Woods units. PAH has three subgroups: idiopathic, heritable, and pulmonary arterial hypertension related to risk factors or associated conditions.

Some of the key facts of the Pulmonary Arterial Hypertension Market Report: 

• The Pulmonary Arterial Hypertension market size was valued at USD 4,901 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total prevalence in the United States was calculated to be 53,219 cases with only 31,931 confirmed diagnosed cases in 2019
• In the year 2021, the total prevalent cases of Pulmonary Arterial Hypertension (PAH) were 69,605 cases in the 7MM which will increase by 2032
• The female patient pool accounted to be around 80% of the total diagnosed cases in the United States
• Key Pulmonary Arterial Hypertension Companies: Acceleron Pharma Inc., United Therapeutics, Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, and others
• Key Pulmonary Arterial Hypertension Therapies: Sotatercept, Ralinepag, Rodatristat Ethy, AV-101, RT234, and others
• The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that the prevalence of Pulmonary Arterial Hypertension (PAH) is more among female as compared to male

Get a Free sample for the Pulmonary Arterial Hypertension Market Report 

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market

Key benefits of the Pulmonary Arterial Hypertension Market report:

1. Pulmonary Arterial Hypertension market report covers a descriptive overview and comprehensive insight of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Pulmonary Arterial Hypertension market report provides insights on the current and emerging therapies.
3. Pulmonary Arterial Hypertension market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Pulmonary Arterial Hypertension market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market.

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiological Insights 

Pulmonary Arterial Hypertension Market  

The dynamics of the Pulmonary Arterial Hypertension market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The PAH treatment market looks promising as the market is emerging with newer treatments that have recently been approved by the FDA to treat PAH, specifically. However, large multicenter trials are still necessary to examine the overarching patterns and treatment response as a whole.” 

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Pulmonary Arterial Hypertension
• Prevalent Cases of Pulmonary Arterial Hypertension by severity
• Gender-specific Prevalence of Pulmonary Arterial Hypertension
• Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension market forecast 

Pulmonary Arterial Hypertension Therapies and Key Companies

• Sotatercept: Acceleron Pharma Inc.
• Ralinepag: United Therapeutics
• Rodatristat Ethy: Altavant Sciences
• AV-101: Aerovate Therapeutics
• RT234: Respira Therapeutics

Scope of the Pulmonary Arterial Hypertension Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Arterial Hypertension Companies: Acceleron Pharma Inc., United Therapeutics, Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, and others
• Key Pulmonary Arterial Hypertension Therapies: Sotatercept, Ralinepag, Rodatristat Ethy, AV-101, RT234, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Pulmonary Arterial Hypertension Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Arterial Hypertension Market Access and Reimbursement 

Table of Contents 

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Disease Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension 

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2019–2032)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17.  Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Pulmonary Arterial Hypertension treatment, visit @ Pulmonary Arterial Hypertension Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/